PureTech Health plc (FRA:0VQ)

Market Cap	369.90M -7.9%
Revenue (ttm)	3.97M -3.5%
Net Income	-93.46M
EPS	-0.39
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.480
Previous Close	1.500
Day's Range	1.480 - 1.480
52-Week Range	1.180 - 1.650
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformati...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 90
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0VQ

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 16, 2026

Data Sources Report a data error